Takeda beefs up gout franchise with URL acquisition

Date April 12, 2012

With the patent expiry of its lead drug Actos looming Takeda is living up to its promise of finding new products to fill the almost $4bn void that will be left by the diabetes drug. Yesterday, the Japanese pharma group announced that it would be paying an initial $800m for private US company URL Pharma.

While the acquisition may appear to be small beer for the likes of $34bn Takeda, the deal will contribute strongly to earnings quickly. It was struck principally for the gout treatment, Colcrys, which should provide a complimentary product to Takeda’s existing gout franchise that already includes Uloric.

This content is written, edited and published by EP Vantage and is distributed by Evaluate Ltd. All queries regarding the content should be directed to: news@epvantage.com

EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.

Drawing on Evaluate, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.

EP Vantage SM ©2018 EP Vantage Ltd